Liraglutid (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Liraglutid" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

16nih.gov

4^th place

8^th place

9doi.org

2^nd place

5^th place

4europa.eu

68^th place

28^th place

4semanticscholar.org

11^th place

51^st place

2nejm.org

2,374^th place

1,034^th place

2worldcat.org

5^th place

10^th place

1drugs.com

399^th place

169^th place

1fda.gov

447^th place

409^th place

1termania.net

low place

34^th place

1web.archive.org

1^st place

2^nd place

1webmd.com

1,169^th place

312^th place

1diabetesjournals.org

low place

4,177^th place

1crcpress.com

low place

crcpress.com

Goldstein BJ, Mueller-Wieland D (14. november 2007). Type 2 Diabetes: Principles and Practice (2. izd.). CRC Press. ISBN 978-0-8493-7958-1. Pridobljeno 17. januarja 2015.

diabetesjournals.org

American Diabetes Association Professional Practice Committee (1. januar 2022). »9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022«. Diabetes Care. 45 (Suppl 1): S1–S2. doi:10.2337/dc22-Sint. PMID 34964812. S2CID 245454068. Pridobljeno 16. januarja 2023.

doi.org

Shyangdan D, Cummins E, Royle P, Waugh N (Maj 2011). »Liraglutide for the treatment of type 2 diabetes«. Health Technology Assessment. 15 (Suppl 1): 77–86. doi:10.3310/hta15suppl1/09. PMID 21609656.
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A (Oktober 2011). »Glucagon-like peptide analogues for type 2 diabetes mellitus«. The Cochrane Database of Systematic Reviews. 2011 (10): CD006423. doi:10.1002/14651858.cd006423.pub2. PMC 6486297. PMID 21975753.
Marso, Steven P.; Daniels, Gilbert H.; Brown-Frandsen, Kirstine; Kristensen, Peter; Mann, Johannes F. E.; Nauck, Michael A.; Nissen, Steven E.; Pocock, Stuart; Poulter, Neil R. (28. julij 2016). »Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes«. New England Journal of Medicine (v angleščini). 375 (4): 311–322. doi:10.1056/nejmoa1603827. PMC 4985288. PMID 27295427.
American Diabetes Association Professional Practice Committee (1. januar 2022). »9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022«. Diabetes Care. 45 (Suppl 1): S1–S2. doi:10.2337/dc22-Sint. PMID 34964812. S2CID 245454068. Pridobljeno 16. januarja 2023.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (april 2013). »Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study«. JAMA Internal Medicine. 173 (7): 534–539. doi:10.1001/jamainternmed.2013.2720. PMID 23440284.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (Februar 2014). »Pancreatic safety of incretin-based drugs--FDA and EMA assessment«. The New England Journal of Medicine. 370 (9): 794–797. doi:10.1056/NEJMp1314078. PMID 24571751.
Beglinger C, Degen L (november 2006). »Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?«. Physiology & Behavior. 89 (4): 460–464. doi:10.1016/j.physbeh.2006.05.048. PMID 16828127. S2CID 32598231.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

drugs.com

»Liraglutide Monograph for Professionals«. Drugs.com. American Society of Health-System Pharmacists. Pridobljeno 23. marca 2019.

europa.eu

ema.europa.eu

»Victoza EPAR«. Evropska agencija za zdravila. Pridobljeno 23. marca 2019.
»Saxenda EPAR«. Evropska agencija za zdravila (EMA). Pridobljeno 5. junija 2021.
https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_sl.pdf Povzetek gavnih značilnosti zdravila Saxenda, vpogled: 21. 3. 2023.
https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Victoza, vpogled: 21. 3. 2023.

fda.gov

»FDA approves weight management drug«. Ameriški Urad za hrano in zdravila (FDA). 4. december 2020. Pridobljeno 5. junija 2021.

nejm.org

Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.

nih.gov

pubmed.ncbi.nlm.nih.gov

Shyangdan D, Cummins E, Royle P, Waugh N (Maj 2011). »Liraglutide for the treatment of type 2 diabetes«. Health Technology Assessment. 15 (Suppl 1): 77–86. doi:10.3310/hta15suppl1/09. PMID 21609656.
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A (Oktober 2011). »Glucagon-like peptide analogues for type 2 diabetes mellitus«. The Cochrane Database of Systematic Reviews. 2011 (10): CD006423. doi:10.1002/14651858.cd006423.pub2. PMC 6486297. PMID 21975753.
Marso, Steven P.; Daniels, Gilbert H.; Brown-Frandsen, Kirstine; Kristensen, Peter; Mann, Johannes F. E.; Nauck, Michael A.; Nissen, Steven E.; Pocock, Stuart; Poulter, Neil R. (28. julij 2016). »Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes«. New England Journal of Medicine (v angleščini). 375 (4): 311–322. doi:10.1056/nejmoa1603827. PMC 4985288. PMID 27295427.
American Diabetes Association Professional Practice Committee (1. januar 2022). »9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022«. Diabetes Care. 45 (Suppl 1): S1–S2. doi:10.2337/dc22-Sint. PMID 34964812. S2CID 245454068. Pridobljeno 16. januarja 2023.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (april 2013). »Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study«. JAMA Internal Medicine. 173 (7): 534–539. doi:10.1001/jamainternmed.2013.2720. PMID 23440284.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (Februar 2014). »Pancreatic safety of incretin-based drugs--FDA and EMA assessment«. The New England Journal of Medicine. 370 (9): 794–797. doi:10.1056/NEJMp1314078. PMID 24571751.
Beglinger C, Degen L (november 2006). »Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?«. Physiology & Behavior. 89 (4): 460–464. doi:10.1016/j.physbeh.2006.05.048. PMID 16828127. S2CID 32598231.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

ncbi.nlm.nih.gov

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A (Oktober 2011). »Glucagon-like peptide analogues for type 2 diabetes mellitus«. The Cochrane Database of Systematic Reviews. 2011 (10): CD006423. doi:10.1002/14651858.cd006423.pub2. PMC 6486297. PMID 21975753.
Marso, Steven P.; Daniels, Gilbert H.; Brown-Frandsen, Kirstine; Kristensen, Peter; Mann, Johannes F. E.; Nauck, Michael A.; Nissen, Steven E.; Pocock, Stuart; Poulter, Neil R. (28. julij 2016). »Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes«. New England Journal of Medicine (v angleščini). 375 (4): 311–322. doi:10.1056/nejmoa1603827. PMC 4985288. PMID 27295427.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.

dailymed.nlm.nih.gov

»Victoza- liraglutide injection«. DailyMed. Pridobljeno 5. junija 2021.
»Saxenda- liraglutide injection, solution«. DailyMed. Pridobljeno 5. junija 2021.
»DailyMed - liraglutide injection«. dailymed.nlm.nih.gov. Pridobljeno 23. marca 2019.

semanticscholar.org

api.semanticscholar.org

American Diabetes Association Professional Practice Committee (1. januar 2022). »9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022«. Diabetes Care. 45 (Suppl 1): S1–S2. doi:10.2337/dc22-Sint. PMID 34964812. S2CID 245454068. Pridobljeno 16. januarja 2023.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.
Beglinger C, Degen L (november 2006). »Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?«. Physiology & Behavior. 89 (4): 460–464. doi:10.1016/j.physbeh.2006.05.048. PMID 16828127. S2CID 32598231.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/7952907/liraglutid?query=liraglutid&SearchIn=My Slovenski medicinski e-slovar, vpogled: 21. 3. 2023.

web.archive.org

»Understanding Diabetes -- Diagnosis and Treatment«. WebMD. 13. november 2021. Arhivirano iz prvotnega spletišča dne 16. maja 2013. Pridobljeno 16. januarja 2023.

webmd.com

diabetes.webmd.com

»Understanding Diabetes -- Diagnosis and Treatment«. WebMD. 13. november 2021. Arhivirano iz prvotnega spletišča dne 16. maja 2013. Pridobljeno 16. januarja 2023.

worldcat.org

Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1063–1074. doi:10.1056/NEJMoa2200433. ISSN 0028-4793. PMC 9829320. PMID 36129996. S2CID 252437415.
Nathan, David M.; in sod. (The GRADE Study Research Group) (22. september 2022). »Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes«. New England Journal of Medicine (v angleščini). 387 (12): 1075–1088. doi:10.1056/NEJMoa2200436. ISSN 0028-4793. PMC 9832916. PMID 36129997. S2CID 252437195.